Cited by 137Rheumatoid Arthritis Research and TherapiesAutoimmune and Inflammatory Disorders ResearchNatural Compounds in Disease Treatment

Machine learning to predict anti-tumor necrosis factor drug responses of rheumatoid arthritis patients by integrating clinical and genetic markers

Open access
Guan, Yuanfang, Zhang, Hongjiu, Quang, Daniel, Wang, Ziyan, Parker, Stephen C. J., Pappas, Dimitrios A., Kremer, Joel M., Zhu, Fan·2019·Arthritis & Rheumatology

Abstract

Objective: Accurate prediction of treatment responses in rheumatoid arthritis (RA) patients can provide valuable information on effective drug selection. Anti–tumor necrosis factor (anti‐TNF) drugs are an important second‐line treatment after methotrexate, the classic first‐line treatment for RA. However, patient heterogeneity hinders identification of predictive biomarkers and accurate modeling of anti‐TNF drug responses. This study was undertaken to investigate the usefulness of machine learning to assist in developing predictive models for treatment response. Methods: Using data on patient demographics, baseline disease assessment, treatment, and single‐nucleotide polymorphism (SNP) array from the Dialogue on Reverse Engineering Assessment and Methods (DREAM): Rheumatoid Arthritis Responder Challenge, we created a Gaussian process regression model to predict changes in the Disease Activity Score in 28 joints (DAS 28) for the patients and to classify them into either the responder or the nonresponder group. This model was developed and cross‐validated using data from 1,892 RA patients. It was evaluated using an independent data set from 680 patients. We examined the effectiveness of the similarity modeling and the contribution of individual features. Results: In the cross‐validation tests, our method predicted changes in DAS 28 (Δ DAS 28), with a correlation coefficient of 0.405. It correctly classified responses from 78% of patients. In the independent test, this method achieved a Pearson's correlation coefficient of 0.393 in predicting Δ DAS 28. Gaussian process regression effectively remapped the feature space and identified subpopulations that do not respond well to anti‐TNF treatments. Genetic SNP biomarkers showed small contributions in the prediction when added to the clinical models. This was the best‐performing model in the DREAM Challenge. Conclusion: The model described here shows promise in guiding treatment decisions in clinical practice, based primarily on clinical profiles with additional genetic information.

Integrity signals

Registry

Crossref · 10.1002/art.41056

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

2 of the 59 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Guan, Y., Zhang, H., Quang, D., Wang, Z., Parker, S. C. J., Pappas, D. A., Kremer, J. M., & Zhu, F.
Affiliations
  • University of Michigan (US)
  • Columbia University Irving Medical Center (US)
  • Center for Rheumatology (US)
  • Chinese Academy of Sciences (CN)
Corresponding author
Guan, Yuanfang
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2019-11-04
Volume
71
Issue
12
Pages
1987-1996
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W2964201896
Cited by
137
References
59
Citations by year
2026: 8 · 2025: 20 · 2024: 18 · 2023: 20 · 2022: 23 · 2021: 36 · 2020: 11 · 2019: 1
FWCI
13.47
Type
journal article
Language
en
Open access
Locations
  • Arthritis & Rheumatology (publishedVersion)
  • PubMed (publishedVersion)
  • Deep Blue (University of Michigan) (submittedVersion)
Funders
National Natural Science Foundation of China (61802360)
Topics
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
  • Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
Keywords
rheumatoid arthritis, treatment response prediction, DAS28, Gaussian process regression, single nucleotide polymorphisms, genetic biomarkers, clinical biomarkers, personalized treatment selection
MeSH terms
Certolizumab Pegol, Etanercept, Adalimumab, Infliximab, Machine Learning, Arthritis, Rheumatoid, Female, Genetic Markers, Humans, Male, Methotrexate, Middle Aged, Predictive Value of Tests, Regression Analysis, Severity of Illness Index, Tumor Necrosis Factor-alpha, Reproducibility of Results, Normal Distribution, Treatment Outcome, Outcome Assessment, Health Care, Antirheumatic Agents, Polymorphism, Single Nucleotide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review